Key Highlights
- Cambridge Nutritional Sciences plc (LSE:CNSL) reported FY26 revenue of about £7.0 million, down from £8.3 million.
- Gross margin improved to 67.8% from 65.3%.
- Adjusted EBITDA swung to a loss of about £0.4 million from a profit of £0.4 million.
- Net cash fell to £2.6 million from £4.9 million as the company kept investing in its platform.
- Underlying revenue grew about 11% when disrupted regions are excluded, and the half-year to 30 September 2026 has now closed.
Why Cambridge Nutritional Sciences Is in Focus Today
Cambridge Nutritional Sciences plc (LSE:CNSL) is on the radar of AIM healthcare investors on 20 October 2026 because its first half of FY27 has just ended. After a year in which geopolitical disruption hit headline revenue, investors want evidence that underlying growth can show through and that cash burn is under control. The company typically updates on trading after the half-year, making this a key moment for the shares.
Company Background
Formerly Omega Diagnostics, the company changed its name in September 2023 to reflect a sharpened focus. It is a specialist medical diagnostics business promoting a personalised and functional approach to health and nutrition. Its products help practitioners identify food intolerances and other nutritional factors, and it serves markets across the UK, Europe, the Americas, India, Asia, Africa and the Middle East.
FY26 Results Breakdown
For the year to 31 March 2026, revenue fell to about £7.0 million. The decline was linked to geopolitical disruption in certain regions, while excluding those regions, revenue grew about 11%. Gross margin rose 2.5 percentage points to 67.8%, showing pricing power and manufacturing efficiency. Adjusted EBITDA swung to a £0.4 million loss and net cash dropped by £2.3 million to £2.6 million, reflecting continued investment in regulatory and manufacturing capabilities. Audited results followed in July 2026.
Why Margins Matter
Rising gross margins mean each additional sale contributes more to covering fixed costs. If CNSL can restore revenue in disrupted territories while keeping margins near 68%, the business could swing back to profitability relatively quickly. That operating leverage is central to the investment case for LSE:CNSL.
Geographic Exposure
The company sells into many international markets through distributors. Conflict and instability in some regions, including the Middle East, have disrupted orders and logistics in recent years. Diversification provides resilience, but it also means headline revenue can be affected by events outside management's control.
Practitioner Engagement
CNSL runs a Scientific Education Programme, attending and speaking at events for nutritional therapists, integrative health practitioners and complementary medicine professionals. Building relationships with practitioners drives test adoption, especially as interest in personalised nutrition and gut health grows among consumers.
Investment in the Platform
Management has continued to invest in its regulatory standing and manufacturing base. Diagnostic products face increasingly strict regulatory requirements in Europe and elsewhere, and compliance can be a competitive moat once achieved. The cost of that investment has weighed on EBITDA and cash in the short term.
Valuation Perspective
The company's market value is very small relative to its revenue base and net cash, reflecting scepticism about growth and profitability. A return to growth with stable cash could lead to a re-rating, while further cash outflows would increase concern.
Cash Runway Considerations
With net cash of £2.6 million at the end of March 2026 and an adjusted EBITDA loss of about £0.4 million for the year, CNSL is not in immediate funding distress, but the £2.3 million decline in cash during FY26 shows the cost of investment. Investors in LSE:CNSL will want to see cash outflows slow in the first half of FY27 as capital projects complete and revenue recovers. Management has room to manage costs, and higher gross margins provide a cushion, but a prolonged revenue shortfall would eventually raise questions about funding. The interim update should give clarity on how quickly the business can move back toward breakeven and whether any further investment phases are planned.
Consumer Health Tailwinds
Interest in gut health, personalised nutrition and preventative wellness has grown strongly, supporting practitioner-led testing markets where CNSL has decades of experience.
What Investors Are Watching Next
Investors will look for a half-year trading update covering revenue, margins, EBITDA and net cash at 30 September 2026, a recovery in disrupted regions, new distribution agreements, product launches and progress on regulatory milestones. Commentary on the full-year outlook will be closely read.
Risks
Risks include geopolitical disruption, cash burn, competition from consumer testing companies and regulatory costs. Cambridge Nutritional Sciences plc (LSE:CNSL) needs to show underlying growth translating into profit.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...